The objective of this project is the continued development and enhanced productivity of an efficiently functioning consortium of four New England pediatric cancer centers (Brown University/Rhode Island Hospital; Dartmouth-Hitchcock Medical Center-Norris Cotton Cancer Center; Harvard University/Massachusetts General Hospital; University of Vermont/Medical Center Hospital-Vermont Regional Cancer Center) for the purpose of: A. Contributing to the understanding and treatment of childhood malignancies through: 1. Input into national cooperative studies through active membership in the Pediatric Oncology Group (POG): a. Patient Accrual: Achieve significant number and quality of patient entries on protocols. b. Study Development and Evaluation: Assist in the development of new protocols through committee memberships, institutional reviews of proposed protocol designs, analysis of study results, and proposal of new protocols for POG implementation based on NEPOC studies. c. Administration: Accept responsibilities for POG administrative functions. 2. Stimulation and facilitation of cooperative efforts within NEPOC in studies of joint interest in the area of childhood malignancies, in particular toward developing potential pilot studies for POG. B. Enhancement of the care of children with cancer in the geographical areas served by the NEPOC member institutions through: 1. assuring comprehensive and modern management of childhood malignancies as a benefit of membership in a national cooperative pediatric oncology study group; 2. sharing the staff expertise and investigative facilities at each of the NEPOC centers; 3. joint efforts in the promotion of education of the local community in the area of cancer in children. Through a centralized administration, this Consortium will integrate the activities and resources (staff, investigative facilities, patients) at each of the four member institutions into a single program aimed at achieving these goals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA029293-15
Application #
2087900
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1981-01-01
Project End
1995-12-31
Budget Start
1995-01-01
Budget End
1995-12-31
Support Year
15
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Rhode Island Hospital (Providence, RI)
Department
Type
DUNS #
161202122
City
Providence
State
RI
Country
United States
Zip Code
02903
Wacker, Pierre; Land, Vita J; Camitta, Bruce M et al. (2007) Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study. J Pediatr Hematol Oncol 29:627-32
Kung, Faith H; Schwartz, Cindy L; Ferree, Carolyn R et al. (2006) POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group. J Pediatr Hematol Oncol 28:362-8
Ravindranath, Y; Chang, M; Steuber, C P et al. (2005) Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 19:2101-16
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Goorin, Allen M; Schwartzentruber, Douglas J; Devidas, Meenakshi et al. (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574-80
Lacayo, N J; Lum, B L; Becton, D L et al. (2002) Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia 16:920-7
Saylors 3rd, R L; Stine, K C; Sullivan, J et al. (2001) Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 19:3463-9
Mahoney Jr, D H; Cohen, M E; Friedman, H S et al. (2000) Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro Oncol 2:213-20
Land, V J; Thomas, P R; Boyett, J M et al. (1985) Comparison of maintenance treatment regimens for first central nervous system relapse in children with acute lymphocytic leukemia. A Pediatric Oncology Group study. Cancer 56:81-7